J Rheumatol: High prevalence of lupus comorbidities in patients with psoriasis arthritis

The study was designed to assess the prevalence of lupus (SLE) in psoriasis arthritis (PsA) and to compare it with the general population using a database of large health care providersstudy analyzed the PsA queue database (2002-2017) and analyzed demographic, clinical and laboratory performance and the drugs used based on age and gender and randomly selected controlsStatistical analysis according to the situation using t-test, card-side inspectionIn the PsA group, PsA patients without SLE were compared to the incidence of PsA patients who matched the accompanying SLE based on age and follow-up timeUse single-factor and multi-factor conditional logistic regression analysis to evaluate the factors affecting SLE progressThe PsA group and the control group had 4,836 and 24,180 subjects, with a median age of 56 to 15 years, of which 53.8% were womenEighteen patients in the PsA group (0.37%) and 36 subjects in the control group (0.15%) were diagnosed with SLE (p-0.001)SLE patients without PsA were more resistant to dsDNA and anticardioid phospholipid antibodiesThe use rate of drugs known to induce SLE potential in the PsA group was higher than in the control groupIn PsA patients, older age, short course of PsA disease and the use of statins are associated with SLEthe prevalence of SLE in PsA patients increased by 2.3 times compared to the control groupRisk factors for The emergence of SLE include older psA diagnosis, short course of PsA disease and the use of statinsThe association between PsA and SLE may affect treatment choice and drug development